GE Healthcare JV rolls out digital pathology software for cancer diagnosis

Omnyx CEO Mamar Gelaye

GE Healthcare ($GE) is rolling out digital pathology software that could help doctors diagnose cancer more quickly. The move comes a few months after GE launched cloud-based radiology apps to give healthcare providers more options for analysis and data storage.

Omnyx, a joint venture between GE Healthcare and the University of Pittsburgh Medical Center (UPMC), are developing software called Dynamyx that can help doctors diagnose cancer digitally. Physicians can view images and talk to one another in real-time to try to find the correct diagnosis.

"As cancer care increases in volume and complexity, the essential need for technology and innovation mounts," Omnyx CEO Mamar Gelaye said in a statement. "We at Omnyx understand the burden on clinicians and the stakes for patients. Dynamyx represents our direct response to this growing need for healthcare providers."

Omnyx kicked off operations in 2008 after GE and UPMC struck a $20 million deal. The company was aiming to create a "virtual microscope" used to scan and store images electronically.

Omnyx Pathologist Workstation--Courtesy of GE Healthcare

Omnyx has since grown by leaps and bounds, heeding the industry's call for more computer-based diagnostic and imaging tools. In March 2015, the company revealed that diagnostic lab company Clarient would use its proprietary software to help pathologists make cancer diagnoses.

"The clinical reality is that fighting cancer begins with an accurate diagnosis. Cancer diagnosis and treatment is most effective as it becomes more personalized--and that means the role of the pathologist is crucial," Clarient CMO Kenneth Bloom said at the time.

In November, GE Healthcare launched its Health Cloud with four radiology apps. Omnyx developed the apps, which include one for image postprocessing and another for storing and analyzing a patient's imaging data.

- here's the statement

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.